[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nephrotic-syndrome-steroid-resistant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nephrotic-syndrome-steroid-resistant":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":4},"100576988","biomarkers-and-outcome-predictors-of-pediatric-nephrotic-syndrome-a-genetic-transcriptomic-and-secretome-multiomics-study-100576988",false,"NCT06792448","Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study","PRECISE","Inclusion Criteria:\n\n* Clinical diagnosis of idiopathic nephrotic syndrome (INS) with nephrotic range proteinuria (uPr\u002FuCr ratio \\> 2 mg\u002Fmg).\n* Hypoalbuminemia with serum albumin \\\u003C 3.0 g\u002FdL.\n* Presence of edema.\n* No prior treatment for idiopathic nephrotic syndrome.\n* Age between 1 and 18 years at the time of enrollment.\n* igned informed consent by a parent or legal guardian.\n\nExclusion Criteria:\n\n* Diagnosis of congenital or infantile nephrotic syndrome (age \\\u003C 1 year).\n* Diagnosis of secondary nephrotic syndrome.\n* Presence of glomerulonephritis, autoimmune diseases, or vasculitis.\n* Lack of signed informed consent by a parent or legal guardian.\n* Previous treatment with prednisone or prednisolone for nephrotic syndrome.",true,"ALL","18 Years",{"count":20,"type":21},350,"ESTIMATED","1 Year","OBSERVATIONAL","Idiopathic Nephrotic Syndrome is a rare disease of the kidneys, which typically affects children. For most affected children there is the need of a prolonged treatment with drugs reducing the activity of the immune system, also resulting in many side effects. Those patients, who do not respond to treatment, are at risk of kidney damage and of dialysis or kidney transplantation. It is currently impossible to predict the response to treatment, leading to unnecessary therapies with side effects as well as unclear prognosis in the affected children. The response of the idiopathic nephrotic syndrome to medications acting on the immune system explains its important role in the occurrence of the disease.\n\nWith this study we aim to obtain predictors of the response to treatment right at the beginning of the disease, to adapt the therapy avoiding needless side effects. This will be done evaluating the blood and urine of affected children using state of the art molecular characterisation. We will evaluate the genetic predisposition, the cell trait changes and the presence of molecules in blood and urine that may affect the interaction between the immune system and the kidneys. We expect that the findings will improve treatment of children with idiopathic nephrotic syndrome and reduce the number of children suffering from unnecessary drugs related side effects.",[26,27,28,29,30,31,32,33],"Nephrotic Syndrome Steroid-Dependent","Nephrotic Syndrome Steroid-Resistant","Nephrotic Syndrome in Children","Glomerulonephritis","Proteinuria","Hypoalbuminemia","Kidney Diseases","Chronic Kidney Disease",[35,36,37,38,39,40,41,42,43,44,45,46,47,48,49],"Pediatric nephrotic syndrome","Idiopathic nephrotic syndrome","Steroid-resistant nephrotic syndrome","Steroid-sensitive nephrotic syndrome","Biomarkers discovery","Genetic risk factors","Epigenetic analysis","Adaptive immune system profiling","Liquid biopsy","Serum and urine proteomics","Multiomics approach","Personalized treatment","Disease progression prediction","Molecular characterization","Pediatric kidney disease","NOT_YET_RECRUITING","2025-01-28",{"date":53,"type":54},"2025-01-30","ACTUAL",{"date":56,"type":21},"2025-02-15",{"date":58,"type":21},"2028-06-01",{"name":60,"class":61},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER",{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":68,"enrollmentInfo":69,"targetDuration":71,"studyType":23,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100528574","arrest-nephrosis---austrian-resistant-nephrotic-syndrome-treatment-response-registry-and-biobank-100528574","NCT06162546","ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank","Inclusion Criteria:\n\n* Resistant to standard Immunosuppressive agents (if clinically indicated, e.g. primary\u002Fnon-genetic forms)\n* Persistent urinary protein-to-creatinine (UP\u002FC) ratio \\>1.0 g\u002Fg\n* eGFR \\> 30 ml\u002Fmin per 1.73 m2\n* biopsy or a disease-causing genetic mutation associated with nephrotic syndrome\n\nExclusion Criteria:\n\n* Inability or unwillingness to comply with repeated assessments\n* Objections against participation at discretion of the investigator\n* Secondary\n* Patients with steroid-dependence\u002Ffrequently relapsing disease (but achievement of complete remission)","75 Years",{"count":70,"type":21},100,"10 Years","Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired renal function.\n\nThe AustRian RESistanT NEPHROtic Syndrome Treatment Response RegIStry and Biobank (ARREST-NEPHROSIS) sets out to achieve the following goals, as typical categories of rare disease registries\n\n1. Obtaining real world data on practice patterns and outcomes\n2. Networking between affected patients, families, and clinicians.\n3. Establish a patient base for facilitated recruitment in studies of drugs, medical devices, and products\n4. Development of a Biobank to enable research of potential biomarkers and therapy or disease courses",[74,30,75,27],"Focal Segmental Glomerulosclerosis","Nephrotic Syndrome","RECRUITING","2023-11-30",{"date":79,"type":54},"2023-12-08",{"date":81,"type":54},"2023-01-01",{"date":83,"type":21},"2033-12-31",{"name":85,"class":61},"Christoph Aufricht",1]